InsiderSignal.AI

InsiderSignal.ai

CRDF - Cardiff Oncology, Inc.

Insider Purchase by Pace Gary W (Dir)

1 Year
After Trade
Before Trade

Loading data...

Trade Summary

6 months ago, Pace Gary W, serving as Dir at Cardiff Oncology, Inc. (CRDF), purchased 290,000 shares at $2.45 per share, for a total transaction value of $710,500.00. Following this transaction, Pace Gary W now holds 2,676,352 shares of CRDF.

This purchase represents a 12.00% increase in Pace Gary W's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, July 30, 2025 and publicly disclosed via SEC Form 4 filing on Thursday, July 31, 2025, 1 day after the trade was made.

Cardiff Oncology, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Pace Gary W

Dir

Gary W. Pace, PhD is an Independent Director at Cardiff Oncology, Inc. (CRDF), having joined the board in 2020.[[1]](https://cardiffoncology.com/board-of-directors/) A seasoned biopharmaceutical executive with over 40 years of experience, Dr. Pace has co-founded several early-stage life science companies, guiding products from laboratory development to commercialization.[[1]](https://cardiffoncology.com/board-of-directors/) He currently serves as a director of Pacira Biosciences, Inc. (NASDAQ: PCRX) and Simavita Ltd. (ASX: SVA), and previously held board positions at ResMed Inc. (1994-2018), Transition Therapeutics Inc. (2002-2016), ORxPharma Ltd. (2001-2013), Antisense Therapeutics (2015-2022), and Simavita Ltd. (2015-2021).[[1]](https://cardiffoncology.com/board-of-directors/)[[2]](https://www.pacificchannel.com/team/dr-gary-pace) Dr. Pace has been recognized with the 2003 Centenary Medal from the Australian Government for service to research and development, and the 2011 Director of the Year award for corporate governance by the San Diego Directors Forum.[[1]](https://cardiffoncology.com/board-of-directors/) Dr. Pace holds a B.Sc. (Hons I) from the University of New South Wales and a Ph.D. from the Massachusetts Institute of Technology, where he was a Fulbright Fellow and General Foods Scholar.[[1]](https://cardiffoncology.com/board-of-directors/) On July 30, 2025, as a Director of Cardiff Oncology, he purchased 290,000 shares at $2.45 per share, valued at $710,500, demonstrating confidence in the company.[[3]](https://www.secform4.com/insider-trading/1184778.htm)[[4]](https://www.tradingview.com/news/tradingview:7a708ab288c25:0-cardiff-oncology-director-gary-w-pace-buys-290-000-shares/)

View full insider profile →

Trade Price

$2.45

Quantity

290,000

Total Value

$710,500.00

Shares Owned

2,676,352

Trade Date

Wednesday, July 30, 2025

207 days ago

SEC Filing Date

Thursday, July 31, 2025

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Cardiff Oncology, Inc.

Company Overview

No company information available
View news mentioning CRDF

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/94426

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime